A recently published study (EudraCT 2015-002127-26) compared IVGCs with belimumab (BMB), a fully human IgG1 monoclonal antibody against BAFF (B-cell activating factor) that has been approved for the treatment of systemic lupus erythematosus (SLE), as a treatment for active moderate-to-severe TED. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.